Aclarion Publishes CEO Letter; Notes Q3 Scan Volumes Up 85% YoY And Up 117% YtD

Aclarion's CEO Brent Ness reported a strong Q3 for 2026, with scan volumes increasing by 85% year-over-year and 117% year-to-date. The company is advancing its clinical program, including the CLARITY trial, which is now enrolling at eleven sites with revised criteria to enhance recruitment. Aclarion is focused on expanding its clinical evidence base to support reimbursement efforts in the UK and US, while maintaining a strong balance sheet and disciplined capital allocation.